QURE
uniQure N.V.
$27.66
+14.53%
2026-05-08
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Key Fundamentals
Forward P/E
-7.83
EPS (TTM)
$-3.49
ROE
-207.1%
Revenue Growth (YoY)
6.6%
Profit Margin
0.0%
Debt/Equity
269.78
Price/Book
7.76
Beta
0.87
Market Cap
$1.56B
Avg Volume (10D)
2.0M
Recent Breakout Signals
No recent breakout signals detected for QURE.
Recent Price Range (60 Days)
60D High
$29.44
60D Low
$8.73
Avg Volume
3.2M
Latest Close
$27.66
Get breakout alerts for QURE
Sign up for Breakout Scanner to receive daily notifications when QURE triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
uniQure N.V. (QURE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors QURE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. QURE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.